{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:24:08Z","timestamp":1793823848815,"version":"4.6.1"},"reference-count":188,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T00:00:00Z","timestamp":1663545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T00:00:00Z","timestamp":1663545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIH\/NIA","award":["RF1AG057576"],"award-info":[{"award-number":["RF1AG057576"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Fluids Barriers CNS"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mucopolysaccharidoses comprise a set of genetic diseases marked by an enzymatic dysfunction in the degradation of glycosaminoglycans in lysosomes. There are eight clinically distinct types of mucopolysaccharidosis, some with various subtypes, based on which lysosomal enzyme is deficient and symptom severity. Patients with mucopolysaccharidosis can present with a variety of symptoms, including cognitive dysfunction, hepatosplenomegaly, skeletal abnormalities, and cardiopulmonary issues. Additionally, the onset and severity of symptoms can vary depending on the specific disorder, with symptoms typically arising during early childhood. While there is currently no cure for mucopolysaccharidosis, there are clinically approved therapies for the management of clinical symptoms, such as enzyme replacement therapy. Enzyme replacement therapy is typically administered intravenously, which allows for the systemic delivery of the deficient enzymes to peripheral organ sites. However, crossing the blood\u2013brain barrier (BBB) to ameliorate the neurological symptoms of mucopolysaccharidosis continues to remain a challenge for these large macromolecules. In this review, we discuss the transport mechanisms for the delivery of lysosomal enzymes across the BBB. Additionally, we discuss the several therapeutic approaches, both preclinical and clinical, for the treatment of mucopolysaccharidoses.<\/jats:p>","DOI":"10.1186\/s12987-022-00373-5","type":"journal-article","created":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T03:13:30Z","timestamp":1663557210000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Mucopolysaccharidoses and the blood\u2013brain barrier"],"prefix":"10.1186","volume":"19","author":[{"given":"Onur","family":"Sahin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah P.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant W.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Urayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,19]]},"reference":[{"issue":"3","key":"373_CR1","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jama.281.3.249","volume":"281","author":"PJ Meikle","year":"1999","unstructured":"Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281(3):249\u201354.","journal-title":"JAMA"},{"key":"373_CR2","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.biochi.2016.09.011","volume":"130","author":"EM Kuech","year":"2016","unstructured":"Kuech EM, Brogden G, Naim HY. Alterations in membrane trafficking and pathophysiological implications in lysosomal storage disorders. Biochimie. 2016;130:152\u201362.","journal-title":"Biochimie"},{"key":"373_CR3","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1146\/annurev.bi.60.070191.001353","volume":"60","author":"EF Neufeld","year":"1991","unstructured":"Neufeld EF. Lysosomal storage diseases. Annu Rev Biochem. 1991;60:257\u201380.","journal-title":"Annu Rev Biochem"},{"key":"373_CR4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1750-1172-5-16","volume":"5","author":"MT Vanier","year":"2010","unstructured":"Vanier MT. Niemann-Pick disease type C. Orphanet J Rare Dis. 2010;5:16.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"373_CR5","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/BF00309338","volume":"89","author":"K Suzuki","year":"1995","unstructured":"Suzuki K, Parker CC, Pentchev PG, Katz D, Ghetti B, D\u2019Agostino AN, et al. Neurofibrillary tangles in Niemann-Pick disease type C. Acta Neuropathol. 1995;89(3):227\u201338.","journal-title":"Acta Neuropathol"},{"issue":"Pt 1","key":"373_CR6","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/brain\/118.1.119","volume":"118","author":"S Love","year":"1995","unstructured":"Love S, Bridges LR, Case CP. Neurofibrillary tangles in Niemann-Pick disease type C. Brain. 1995;118(Pt 1):119\u201329.","journal-title":"Brain"},{"issue":"3","key":"373_CR7","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0002-9440(10)63163-X","volume":"164","author":"RA Nixon","year":"2004","unstructured":"Nixon RA. Niemann-Pick Type C disease and Alzheimer\u2019s disease: the APP-endosome connection fattens up. Am J Pathol. 2004;164(3):757\u201361.","journal-title":"Am J Pathol"},{"issue":"12","key":"373_CR8","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1136\/jmg.2004.024455","volume":"41","author":"O Goker-Alpan","year":"2004","unstructured":"Goker-Alpan O, Schiffmann R, LaMarca ME, Nussbaum RL, McInerney-Leo A, Sidransky E. Parkinsonism among Gaucher disease carriers. J Med Genet. 2004;41(12):937\u201340.","journal-title":"J Med Genet"},{"issue":"4","key":"373_CR9","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3390\/cells8040364","volume":"8","author":"GM Riboldi","year":"2019","unstructured":"Riboldi GM, Di Fonzo AB. GBA, Gaucher disease, and Parkinson\u2019s disease: from genetic to clinic to new therapeutic approaches. Cells. 2019;8(4):364.","journal-title":"Cells"},{"issue":"4","key":"373_CR10","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.neuron.2017.01.018","volume":"93","author":"E Aflaki","year":"2017","unstructured":"Aflaki E, Westbroek W, Sidransky E. The complicated relationship between Gaucher disease and Parkinsonism: insights from a rare disease. Neuron. 2017;93(4):737\u201346.","journal-title":"Neuron"},{"issue":"Suppl 5","key":"373_CR11","doi-asserted-by":"publisher","first-page":"v13","DOI":"10.1093\/rheumatology\/ker395","volume":"50","author":"LA Clarke","year":"2011","unstructured":"Clarke LA. Pathogenesis of skeletal and connective tissue involvement in the mucopolysaccharidoses: glycosaminoglycan storage is merely the instigator. Rheumatology. 2011;50(Suppl 5):v13\u20138.","journal-title":"Rheumatology"},{"issue":"6","key":"373_CR12","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s10545-011-9359-8","volume":"34","author":"EA Braunlin","year":"2011","unstructured":"Braunlin EA, Harmatz PR, Scarpa M, Furlanetto B, Kampmann C, Loehr JP, et al. Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management. J Inherit Metab Dis. 2011;34(6):1183\u201397.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"373_CR13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ymgme.2021.03.002","volume":"133","author":"EG Shapiro","year":"2021","unstructured":"Shapiro EG, Eisengart JB. The natural history of neurocognition in MPS disorders: a review. Mol Genet Metab. 2021;133(1):8\u201334.","journal-title":"Mol Genet Metab"},{"issue":"Suppl 5","key":"373_CR14","doi-asserted-by":"publisher","first-page":"v4","DOI":"10.1093\/rheumatology\/ker394","volume":"50","author":"J Muenzer","year":"2011","unstructured":"Muenzer J. Overview of the mucopolysaccharidoses. Rheumatology. 2011;50(Suppl 5):v4-12.","journal-title":"Rheumatology"},{"issue":"42","key":"373_CR15","doi-asserted-by":"publisher","first-page":"30019","DOI":"10.1074\/jbc.M113.499541","volume":"288","author":"EM Wiegmann","year":"2013","unstructured":"Wiegmann EM, Westendorf E, Kalus I, Pringle TH, Lubke T, Dierks T. Arylsulfatase K, a novel lysosomal sulfatase. J Biol Chem. 2013;288(42):30019\u201328.","journal-title":"J Biol Chem"},{"key":"373_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2021-108061","author":"S Verheyen","year":"2021","unstructured":"Verheyen S, Blatterer J, Speicher MR, Bhavani GS, Boons GJ, Ilse MB, et al. Novel subtype of mucopolysaccharidosis caused by arylsulfatase K (ARSK) deficiency. J Med Genet. 2021. https:\/\/doi.org\/10.1136\/jmedgenet-2021-108061.","journal-title":"J Med Genet"},{"issue":"17","key":"373_CR17","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.1042\/BCJ20200546","volume":"477","author":"C Trabszo","year":"2020","unstructured":"Trabszo C, Ramms B, Chopra P, Lullmann-Rauch R, Stroobants S, Spross J, et al. Arylsulfatase K inactivation causes mucopolysaccharidosis due to deficient glucuronate desulfation of heparan and chondroitin sulfate. Biochem J. 2020;477(17):3433\u201351.","journal-title":"Biochem J"},{"issue":"26","key":"373_CR18","doi-asserted-by":"publisher","first-page":"10310","DOI":"10.1073\/pnas.1202071109","volume":"109","author":"B Kowalewski","year":"2012","unstructured":"Kowalewski B, Lamanna WC, Lawrence R, Damme M, Stroobants S, Padva M, et al. Arylsulfatase G inactivation causes loss of heparan sulfate 3-O-sulfatase activity and mucopolysaccharidosis in mice. Proc Natl Acad Sci USA. 2012;109(26):10310\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"373_CR19","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/humu.24150","volume":"42","author":"VG Peter","year":"2021","unstructured":"Peter VG, Quinodoz M, Sadio S, Held S, Rodrigues M, Soares M, et al. New clinical and molecular evidence linking mutations in ARSG to Usher syndrome type IV. Hum Mutat. 2021;42(3):261\u201371.","journal-title":"Hum Mutat"},{"issue":"1","key":"373_CR20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ymgme.2020.02.009","volume":"130","author":"J Cadaoas","year":"2020","unstructured":"Cadaoas J, Boyle G, Jungles S, Cullen S, Vellard M, Grubb JH, et al. Vestronidase alfa: recombinant human beta-glucuronidase as an enzyme replacement therapy for MPS VII. Mol Genet Metab. 2020;130(1):65\u201376.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"373_CR21","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s13023-021-01880-8","volume":"16","author":"Y Puckett","year":"2021","unstructured":"Puckett Y, Mallorga-Hernandez A, Montano AM. Epidemiology of mucopolysaccharidoses (MPS) in United States: challenges and opportunities. Orphanet J Rare Dis. 2021;16(1):241.","journal-title":"Orphanet J Rare Dis"},{"issue":"1\u20132","key":"373_CR22","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s004399900075","volume":"105","author":"BJ Poorthuis","year":"1999","unstructured":"Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, van Weely S, et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet. 1999;105(1\u20132):151\u20136.","journal-title":"Hum Genet"},{"issue":"16","key":"373_CR23","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.2174\/138161208784705504","volume":"14","author":"DJ Begley","year":"2008","unstructured":"Begley DJ, Pontikis CC, Scarpa M. Lysosomal storage diseases and the blood\u2013brain barrier. Curr Pharm Des. 2008;14(16):1566\u201380.","journal-title":"Curr Pharm Des"},{"issue":"10","key":"373_CR24","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40265-019-01147-4","volume":"79","author":"K Sawamoto","year":"2019","unstructured":"Sawamoto K, Stapleton M, Almeciga-Diaz CJ, Espejo-Mojica AJ, Losada JC, Suarez DA, et al. Therapeutic options for mucopolysaccharidoses: current and emerging treatments. Drugs. 2019;79(10):1103\u201334.","journal-title":"Drugs"},{"issue":"7","key":"373_CR25","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1001\/jama.2015.459","volume":"313","author":"PK Mistry","year":"2015","unstructured":"Mistry PK, Lukina E, Ben Turkia H, Amato D, Baris H, Dasouki M, et al. Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial. JAMA. 2015;313(7):695\u2013706.","journal-title":"JAMA"},{"issue":"9","key":"373_CR26","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/pds.1779","volume":"18","author":"CE Hollak","year":"2009","unstructured":"Hollak CE, Hughes D, van Schaik IN, Schwierin B, Bembi B. Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme. Pharmacoepidemiol Drug Saf. 2009;18(9):770\u20137.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"373_CR27","doi-asserted-by":"publisher","DOI":"10.1177\/10600280221108443","author":"LP Leonart","year":"2022","unstructured":"Leonart LP, Fachi MM, Boger B, Silva MRD, Szpak R, Lombardi NF, et al. A systematic review and meta-analyses of longitudinal studies on drug treatments for Gaucher disease. Ann Pharmacother. 2022. https:\/\/doi.org\/10.1177\/10600280221108443.","journal-title":"Ann Pharmacother"},{"issue":"1","key":"373_CR28","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/dmcn.13600","volume":"60","author":"M Beck","year":"2018","unstructured":"Beck M. Treatment strategies for lysosomal storage disorders. Dev Med Child Neurol. 2018;60(1):13\u20138.","journal-title":"Dev Med Child Neurol"},{"issue":"6","key":"373_CR29","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.bbmt.2015.02.011","volume":"21","author":"M Aldenhoven","year":"2015","unstructured":"Aldenhoven M, Jones SA, Bonney D, Borrill RE, Coussons M, Mercer J, et al. Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines. Biol Blood Marrow Transpl. 2015;21(6):1106\u20139.","journal-title":"Biol Blood Marrow Transpl"},{"key":"373_CR30","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3389\/fped.2019.00433","volume":"7","author":"EY Tan","year":"2019","unstructured":"Tan EY, Boelens JJ, Jones SA, Wynn RF. Hematopoietic stem cell transplantation in inborn errors of metabolism. Front Pediatr. 2019;7:433.","journal-title":"Front Pediatr"},{"issue":"7","key":"373_CR31","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/mt.2015.62","volume":"23","author":"G Parenti","year":"2015","unstructured":"Parenti G, Andria G, Valenzano KJ. Pharmacological chaperone therapy: preclinical development, clinical translation, and prospects for the treatment of lysosomal storage disorders. Mol Ther. 2015;23(7):1138\u201348.","journal-title":"Mol Ther"},{"issue":"1","key":"373_CR32","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3390\/ijms21010232","volume":"21","author":"JC Losada Diaz","year":"2019","unstructured":"Losada Diaz JC, Cepeda Del Castillo J, Rodriguez-Lopez EA, Almeciga-Diaz CJ. Advances in the development of pharmacological chaperones for the mucopolysaccharidoses. Int J Mol Sci. 2019;21(1):232.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"373_CR33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/diseases4040033","volume":"4","author":"MF Coutinho","year":"2016","unstructured":"Coutinho MF, Santos JI, Matos L, Alves S. Genetic substrate reduction therapy: a promising approach for lysosomal storage disorders. Diseases. 2016;4(4):33.","journal-title":"Diseases"},{"issue":"11","key":"373_CR34","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.2174\/138920111798376932","volume":"12","author":"J Jakobkiewicz-Banecka","year":"2011","unstructured":"Jakobkiewicz-Banecka J, Piotrowska E, Gabig-Ciminska M, Borysiewicz E, Slominska-Wojewodzka M, Narajczyk M, et al. Substrate reduction therapies for mucopolysaccharidoses. Curr Pharm Biotechnol. 2011;12(11):1860\u20135.","journal-title":"Curr Pharm Biotechnol"},{"issue":"2","key":"373_CR35","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s40259-018-0264-7","volume":"32","author":"WM Pardridge","year":"2018","unstructured":"Pardridge WM, Boado RJ, Giugliani R, Schmidt M. Plasma pharmacokinetics of Valanafusp alpha, a human insulin receptor antibody-iduronidase fusion protein, in Patients with Mucopolysaccharidosis Type I. BioDrugs. 2018;32(2):169\u201376.","journal-title":"BioDrugs"},{"issue":"2","key":"373_CR36","first-page":"671","volume":"29","author":"T Okuyama","year":"2021","unstructured":"Okuyama T, Eto Y, Sakai N, Nakamura K, Yamamoto T, Yamaoka M, et al. A Phase 2\/3 trial of Pabinafusp alfa, IDS fused with anti-human transferrin receptor antibody. Target Neurodegener MPS-II Mol Ther. 2021;29(2):671\u20139.","journal-title":"Target Neurodegener MPS-II Mol Ther"},{"issue":"4","key":"373_CR37","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.ymgme.2018.02.011","volume":"123","author":"C Hendriksz","year":"2018","unstructured":"Hendriksz C, Santra S, Jones SA, Geberhiwot T, Jesaitis L, Long B, et al. Safety, immunogenicity, and clinical outcomes in patients with Morquio A syndrome participating in 2 sequential open-label studies of elosulfase alfa enzyme replacement therapy (MOR-002\/MOR-100), representing 5 years of treatment. Mol Genet Metab. 2018;123(4):479\u201387.","journal-title":"Mol Genet Metab"},{"issue":"447","key":"373_CR38","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1080\/08035320510028139","volume":"94","author":"P Harmatz","year":"2005","unstructured":"Harmatz P, Kramer WG, Hopwood JJ, Simon J, Butensky E, Swiedler SJ. Pharmacokinetic profile of recombinant human N-acetylgalactosamine 4-sulphatase enzyme replacement therapy in patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): a phase I\/II study. Acta Paediatr Suppl. 2005;94(447):61\u20138 (discussion 57).","journal-title":"Acta Paediatr Suppl"},{"issue":"4","key":"373_CR39","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.ymgme.2018.02.006","volume":"123","author":"P Harmatz","year":"2018","unstructured":"Harmatz P, Whitley CB, Wang RY, Bauer M, Song W, Haller C, et al. A novel Blind Start study design to investigate vestronidase alfa for mucopolysaccharidosis VII, an ultra-rare genetic disease. Mol Genet Metab. 2018;123(4):488\u201394.","journal-title":"Mol Genet Metab"},{"issue":"8","key":"373_CR40","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.3390\/ijms21082975","volume":"21","author":"R Parini","year":"2020","unstructured":"Parini R, Deodato F. Intravenous enzyme replacement therapy in mucopolysaccharidoses: clinical effectiveness and limitations. Int J Mol Sci. 2020;21(8):2975.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"373_CR41","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1172\/JCI117237","volume":"93","author":"MS Sands","year":"1994","unstructured":"Sands MS, Vogler C, Kyle JW, Grubb JH, Levy B, Galvin N, et al. Enzyme replacement therapy for murine mucopolysaccharidosis type VII. J Clin Invest. 1994;93(6):2324\u201331.","journal-title":"J Clin Invest"},{"issue":"6","key":"373_CR42","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1203\/00006450-199606000-00019","volume":"39","author":"C Vogler","year":"1996","unstructured":"Vogler C, Sands MS, Levy B, Galvin N, Birkenmeier EH, Sly WS. Enzyme replacement with recombinant beta-glucuronidase in murine mucopolysaccharidosis type VII: impact of therapy during the first six weeks of life on subsequent lysosomal storage, growth, and survival. Pediatr Res. 1996;39(6):1050\u20134.","journal-title":"Pediatr Res"},{"issue":"7","key":"373_CR43","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1172\/JCI119322","volume":"99","author":"MS Sands","year":"1997","unstructured":"Sands MS, Vogler C, Torrey A, Levy B, Gwynn B, Grubb J, et al. Murine mucopolysaccharidosis type VII: long term therapeutic effects of enzyme replacement and enzyme replacement followed by bone marrow transplantation. J Clin Investig. 1997;99(7):1596\u2013605.","journal-title":"J Clin Investig"},{"issue":"6","key":"373_CR44","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1203\/00006450-199906000-00010","volume":"45","author":"C Vogler","year":"1999","unstructured":"Vogler C, Levy B, Galvin NJ, Thorpe C, Sands MS, Barker JE, et al. Enzyme replacement in murine mucopolysaccharidosis type VII: neuronal and glial response to beta-glucuronidase requires early initiation of enzyme replacement therapy. Pediatr Res. 1999;45(6):838\u201344.","journal-title":"Pediatr Res"},{"issue":"Suppl 2","key":"373_CR45","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13052-018-0562-1","volume":"44","author":"D Concolino","year":"2018","unstructured":"Concolino D, Deodato F, Parini R. Enzyme replacement therapy: efficacy and limitations. Ital J Pediatr. 2018;44(Suppl 2):120.","journal-title":"Ital J Pediatr"},{"issue":"34","key":"373_CR46","doi-asserted-by":"publisher","first-page":"12658","DOI":"10.1073\/pnas.0405042101","volume":"101","author":"A Urayama","year":"2004","unstructured":"Urayama A, Grubb JH, Sly WS, Banks WA. Developmentally regulated mannose 6-phosphate receptor-mediated transport of a lysosomal enzyme across the blood-brain barrier. Proc Natl Acad Sci USA. 2004;101(34):12658\u201363.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"373_CR47","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/mt.2008.84","volume":"16","author":"A Urayama","year":"2008","unstructured":"Urayama A, Grubb JH, Sly WS, Banks WA. Mannose 6-phosphate receptor-mediated transport of sulfamidase across the blood-brain barrier in the newborn mouse. Mol Ther. 2008;16(7):1261\u20136.","journal-title":"Mol Ther"},{"issue":"9","key":"373_CR48","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1016\/j.clinthera.2015.06.004","volume":"37","author":"P Harmatz","year":"2015","unstructured":"Harmatz P. Enzyme replacement therapies and immunogenicity in lysosomal storage diseases: is there a pattern? Clin Ther. 2015;37(9):2130\u20134.","journal-title":"Clin Ther"},{"issue":"4","key":"373_CR49","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrd.2015.21","volume":"15","author":"WA Banks","year":"2016","unstructured":"Banks WA. From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery. Nat Rev Drug Discov. 2016;15(4):275\u201392.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"373_CR50","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s00401-018-1812-4","volume":"135","author":"NJ Abbott","year":"2018","unstructured":"Abbott NJ, Pizzo ME, Preston JE, Janigro D, Thorne RG. The role of brain barriers in fluid movement in the CNS: is there a \u201cglymphatic\u201d system? Acta Neuropathol. 2018;135(3):387\u2013407.","journal-title":"Acta Neuropathol"},{"issue":"6","key":"373_CR51","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1111\/tra.12645","volume":"20","author":"S Yazdani","year":"2019","unstructured":"Yazdani S, Jaldin-Fincati JR, Pereira RVS, Klip A. Endothelial cell barriers: transport of molecules between blood and tissues. Traffic. 2019;20(6):390\u2013403.","journal-title":"Traffic"},{"issue":"7","key":"373_CR52","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/jcbfm.2014.71","volume":"34","author":"H Chen","year":"2014","unstructured":"Chen H, Konofagou EE. The size of blood-brain barrier opening induced by focused ultrasound is dictated by the acoustic pressure. J Cereb Blood Flow Metab. 2014;34(7):1197\u2013204.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"7501","key":"373_CR53","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nature13324","volume":"509","author":"A Ben-Zvi","year":"2014","unstructured":"Ben-Zvi A, Lacoste B, Kur E, Andreone BJ, Mayshar Y, Yan H, et al. Mfsd2a is critical for the formation and function of the blood-brain barrier. Nature. 2014;509(7501):507\u201311.","journal-title":"Nature"},{"issue":"3","key":"373_CR54","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.neuron.2017.03.043","volume":"94","author":"BJ Andreone","year":"2017","unstructured":"Andreone BJ, Chow BW, Tata A, Lacoste B, Ben-Zvi A, Bullock K, et al. Blood-brain barrier permeability is regulated by lipid transport-dependent suppression of caveolae-mediated transcytosis. Neuron. 2017;94(3):581\u201394.","journal-title":"Neuron"},{"issue":"10","key":"373_CR55","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/j.neuron.2022.02.017","volume":"110","author":"S Ayloo","year":"2022","unstructured":"Ayloo S, Lazo CG, Sun S, Zhang W, Cui B, Gu C. Pericyte-to-endothelial cell signaling via vitronectin-integrin regulates blood-CNS barrier. Neuron. 2022;110(10):1641\u201355.","journal-title":"Neuron"},{"issue":"5","key":"373_CR56","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41573-021-00139-y","volume":"20","author":"GC Terstappen","year":"2021","unstructured":"Terstappen GC, Meyer AH, Bell RD, Zhang W. Strategies for delivering therapeutics across the blood-brain barrier. Nat Rev Drug Discov. 2021;20(5):362\u201383.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"373_CR57","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1210\/edrv-7-3-314","volume":"7","author":"WM Pardridge","year":"1986","unstructured":"Pardridge WM. Receptor-mediated peptide transport through the blood-brain barrier. Endocr Rev. 1986;7(3):314\u201330.","journal-title":"Endocr Rev"},{"key":"373_CR58","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3389\/fnagi.2019.00373","volume":"11","author":"WM Pardridge","year":"2019","unstructured":"Pardridge WM. Blood-brain barrier and delivery of protein and gene therapeutics to brain. Front Aging Neurosci. 2019;11:373.","journal-title":"Front Aging Neurosci"},{"key":"373_CR59","doi-asserted-by":"crossref","unstructured":"Pardridge WM. A Historical Review of Brain Drug Delivery. Pharmaceutics. 2022;14(6).","DOI":"10.3390\/pharmaceutics14061283"},{"issue":"7","key":"373_CR60","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.3390\/pharmaceutics14071476","volume":"14","author":"RJ Boado","year":"2022","unstructured":"Boado RJ. IgG fusion proteins for brain delivery of biologics via blood-brain barrier receptor-mediated transport. Pharmaceutics. 2022;14(7):1476.","journal-title":"Pharmaceutics"},{"key":"373_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2019.101665","volume":"181","author":"KB Johnsen","year":"2019","unstructured":"Johnsen KB, Burkhart A, Thomsen LB, Andresen TL, Moos T. Targeting the transferrin receptor for brain drug delivery. Prog Neurobiol. 2019;181: 101665.","journal-title":"Prog Neurobiol"},{"issue":"6","key":"373_CR62","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.3390\/pharmaceutics14061240","volume":"14","author":"H Sonoda","year":"2022","unstructured":"Sonoda H, Takahashi K, Minami K, Hirato T, Yamamoto T, So S, et al. Treatment of neuronopathic mucopolysaccharidoses with blood-brain barrier-crossing enzymes: clinical application of receptor-mediated transcytosis. Pharmaceutics. 2022;14(6):1240.","journal-title":"Pharmaceutics"},{"issue":"7","key":"373_CR63","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.3390\/pharmaceutics14071452","volume":"14","author":"A Yogi","year":"2022","unstructured":"Yogi A, Hussack G, van Faassen H, Haqqani AS, Delaney CE, Brunette E, et al. Brain delivery of IGF1R5, a single-domain antibody targeting insulin-like growth factor-1 receptor. Pharmaceutics. 2022;14(7):1452.","journal-title":"Pharmaceutics"},{"issue":"5","key":"373_CR64","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.ymthe.2018.02.032","volume":"26","author":"H Sonoda","year":"2018","unstructured":"Sonoda H, Morimoto H, Yoden E, Koshimura Y, Kinoshita M, Golovina G, et al. A blood-brain-barrier-penetrating anti-human transferrin receptor antibody fusion protein for neuronopathic mucopolysaccharidosis II. Mol Ther. 2018;26(5):1366\u201374.","journal-title":"Mol Ther"},{"issue":"545","key":"373_CR65","doi-asserted-by":"publisher","first-page":"eaay1163","DOI":"10.1126\/scitranslmed.aay1163","volume":"12","author":"JC Ullman","year":"2020","unstructured":"Ullman JC, Arguello A, Getz JA, Bhalla A, Mahon CS, Wang J, et al. Brain delivery and activity of a lysosomal enzyme using a blood-brain barrier transport vehicle in mice. Sci Transl Med. 2020;12(545):eaay1163.","journal-title":"Sci Transl Med."},{"issue":"3","key":"373_CR66","doi-asserted-by":"publisher","first-page":"e20211057","DOI":"10.1084\/jem.20211057","volume":"219","author":"A Arguello","year":"2022","unstructured":"Arguello A, Mahon CS, Calvert MEK, Chan D, Dugas JC, Pizzo ME, et al. Molecular architecture determines brain delivery of a transferrin receptor-targeted lysosomal enzyme. J Exp Med. 2022;219(3):e20211057.","journal-title":"J Exp Med"},{"issue":"5990","key":"373_CR67","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/312162a0","volume":"312","author":"WA Jefferies","year":"1984","unstructured":"Jefferies WA, Brandon MR, Hunt SV, Williams AF, Gatter KC, Mason DY. Transferrin receptor on endothelium of brain capillaries. Nature. 1984;312(5990):162\u20133.","journal-title":"Nature"},{"key":"373_CR68","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1242\/jcs.1985.Supplement_3.17","volume":"3","author":"CR Hopkins","year":"1985","unstructured":"Hopkins CR, Miller K, Beardmore JM. Receptor-mediated endocytosis of transferrin and epidermal growth factor receptors: a comparison of constitutive and ligand-induced uptake. J Cell Sci Suppl. 1985;3:173\u201386.","journal-title":"J Cell Sci Suppl"},{"issue":"1","key":"373_CR69","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1073\/pnas.96.1.254","volume":"96","author":"D Wu","year":"1999","unstructured":"Wu D, Pardridge WM. Neuroprotection with noninvasive neurotrophin delivery to the brain. Proc Natl Acad Sci USA. 1999;96(1):254\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"84","key":"373_CR70","doi-asserted-by":"publisher","first-page":"84ra44","DOI":"10.1126\/scitranslmed.3002230","volume":"3","author":"YJ Yu","year":"2011","unstructured":"Yu YJ, Zhang Y, Kenrick M, Hoyte K, Luk W, Lu Y, et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med. 2011;3(84):84ra44.","journal-title":"Sci Transl Med."},{"issue":"261","key":"373_CR71","doi-asserted-by":"publisher","first-page":"261ra154","DOI":"10.1126\/scitranslmed.3009835","volume":"6","author":"YJ Yu","year":"2014","unstructured":"Yu YJ, Atwal JK, Zhang Y, Tong RK, Wildsmith KR, Tan C, et al. Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates. Sci Transl Med. 2014;6(261):261ra154.","journal-title":"Sci Transl Med."},{"issue":"2","key":"373_CR72","doi-asserted-by":"publisher","first-page":"308","DOI":"10.7150\/thno.17155","volume":"7","author":"G Hultqvist","year":"2017","unstructured":"Hultqvist G, Syvanen S, Fang XT, Lannfelt L, Sehlin D. Bivalent brain shuttle increases antibody uptake by monovalent binding to the transferrin receptor. Theranostics. 2017;7(2):308\u201318.","journal-title":"Theranostics"},{"issue":"2","key":"373_CR73","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1084\/jem.20131660","volume":"211","author":"N Bien-Ly","year":"2014","unstructured":"Bien-Ly N, Yu YJ, Bumbaca D, Elstrott J, Boswell CA, Zhang Y, et al. Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants. J Exp Med. 2014;211(2):233\u201344.","journal-title":"J Exp Med"},{"issue":"4","key":"373_CR74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0096340","volume":"9","author":"H Sade","year":"2014","unstructured":"Sade H, Baumgartner C, Hugenmatter A, Moessner E, Freskgard PO, Niewoehner J. A human blood-brain barrier transcytosis assay reveals antibody transcytosis influenced by pH-dependent receptor binding. PLoS ONE. 2014;9(4): e96340.","journal-title":"PLoS ONE"},{"issue":"7816","key":"373_CR75","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41586-020-2453-z","volume":"583","author":"AC Yang","year":"2020","unstructured":"Yang AC, Stevens MY, Chen MB, Lee DP, Stahli D, Gate D, et al. Physiological blood-brain transport is impaired with age by a shift in transcytosis. Nature. 2020;583(7816):425\u201330.","journal-title":"Nature"},{"issue":"2","key":"373_CR76","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.neuron.2015.09.036","volume":"88","author":"N Bien-Ly","year":"2015","unstructured":"Bien-Ly N, Boswell CA, Jeet S, Beach TG, Hoyte K, Luk W, et al. Lack of widespread BBB disruption in Alzheimer\u2019s disease models: focus on therapeutic antibodies. Neuron. 2015;88(2):289\u201397.","journal-title":"Neuron"},{"issue":"2","key":"373_CR77","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1021\/acs.molpharmaceut.8b00870","volume":"16","author":"P Bourassa","year":"2019","unstructured":"Bourassa P, Alata W, Tremblay C, Paris-Robidas S, Calon F. Transferrin receptor-mediated uptake at the blood-brain barrier is not impaired by Alzheimer\u2019s disease neuropathology. Mol Pharm. 2019;16(2):583\u201394.","journal-title":"Mol Pharm"},{"key":"373_CR78","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/978-1-61779-191-8_26","volume":"763","author":"N Caram-Salas","year":"2011","unstructured":"Caram-Salas N, Boileau E, Farrington GK, Garber E, Brunette E, Abulrob A, et al. In vitro and in vivo methods for assessing FcRn-mediated reverse transcytosis across the blood-brain barrier. Methods Mol Biol. 2011;763:383\u2013401.","journal-title":"Methods Mol Biol"},{"issue":"21","key":"373_CR79","doi-asserted-by":"publisher","first-page":"12079","DOI":"10.1073\/pnas.96.21.12079","volume":"96","author":"RJ Boado","year":"1999","unstructured":"Boado RJ, Li JY, Nagaya M, Zhang C, Pardridge WM. Selective expression of the large neutral amino acid transporter at the blood-brain barrier. Proc Natl Acad Sci USA. 1999;96(21):12079\u201384.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"373_CR80","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.neuron.2015.11.024","volume":"89","author":"YJ Zuchero","year":"2016","unstructured":"Zuchero YJ, Chen X, Bien-Ly N, Bumbaca D, Tong RK, Gao X, et al. Discovery of novel blood-brain barrier targets to enhance brain uptake of therapeutic antibodies. Neuron. 2016;89(1):70\u201382.","journal-title":"Neuron"},{"issue":"7","key":"373_CR81","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1177\/0271678X17700665","volume":"37","author":"P Siupka","year":"2017","unstructured":"Siupka P, Hersom MN, Lykke-Hartmann K, Johnsen KB, Thomsen LB, Andresen TL, et al. Bidirectional apical-basal traffic of the cation-independent mannose-6-phosphate receptor in brain endothelial cells. J Cereb Blood Flow Metab. 2017;37(7):2598\u2013613.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"20","key":"373_CR82","doi-asserted-by":"publisher","first-page":"17487","DOI":"10.1074\/jbc.M110.189381","volume":"286","author":"F Matthes","year":"2011","unstructured":"Matthes F, W\u00f6lte P, B\u00f6ckenhoff A, H\u00fcwel S, Schulz M, Hyden P, et al. Transport of arylsulfatase A across the blood-brain barrier in vitro. J Biol Chem. 2011;286(20):17487\u201394.","journal-title":"J Biol Chem"},{"issue":"2","key":"373_CR83","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ymgme.2011.11.005","volume":"105","author":"DD Koeberl","year":"2012","unstructured":"Koeberl DD, Li S, Dai J, Thurberg BL, Bali D, Kishnani PS. \u03b22 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease. Mol Genet Metab. 2012;105(2):221\u20137.","journal-title":"Mol Genet Metab"},{"issue":"37","key":"373_CR84","doi-asserted-by":"publisher","first-page":"12451","DOI":"10.1039\/D1SC03188K","volume":"12","author":"X Zhang","year":"2021","unstructured":"Zhang X, Liu H, Meena N, Li C, Zong G, Raben N, et al. Chemoenzymatic glycan-selective remodeling of a therapeutic lysosomal enzyme with high-affinity M6P-glycan ligands. Enzyme substrate specificity is the name of the game. Chem Sci. 2021;12(37):12451\u201362.","journal-title":"Chem Sci"},{"issue":"39","key":"373_CR85","doi-asserted-by":"publisher","first-page":"13532","DOI":"10.1074\/jbc.RA119.009811","volume":"295","author":"JC Chen","year":"2020","unstructured":"Chen JC, Luu AR, Wise N, Angelis R, Agrawal V, Mangini L, et al. Intracerebroventricular enzyme replacement therapy with beta-galactosidase reverses brain pathologies due to GM1 gangliosidosis in mice. J Biol Chem. 2020;295(39):13532\u201355.","journal-title":"J Biol Chem"},{"issue":"23","key":"373_CR86","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1093\/hmg\/ddaa277","volume":"29","author":"D Kaminski","year":"2021","unstructured":"Kaminski D, Yaghootfam C, Matthes F, Ressing A, Gieselmann V, Matzner U. Brain cell type-specific endocytosis of arylsulfatase A identifies limitations of enzyme-based therapies for metachromatic leukodystrophy. Hum Mol Genet. 2021;29(23):3807\u201317.","journal-title":"Hum Mol Genet"},{"issue":"7501","key":"373_CR87","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/nature13241","volume":"509","author":"LN Nguyen","year":"2014","unstructured":"Nguyen LN, Ma D, Shui G, Wong P, Cazenave-Gassiot A, Zhang X, et al. Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid. Nature. 2014;509(7501):503\u20136.","journal-title":"Nature"},{"issue":"4","key":"373_CR88","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.neuron.2014.05.012","volume":"82","author":"Z Zhao","year":"2014","unstructured":"Zhao Z, Zlokovic BV. Blood-brain barrier: a dual life of MFSD2A? Neuron. 2014;82(4):728\u201330.","journal-title":"Neuron"},{"issue":"35","key":"373_CR89","doi-asserted-by":"publisher","first-page":"eaba7457","DOI":"10.1126\/sciadv.aba7457","volume":"6","author":"Z Wang","year":"2020","unstructured":"Wang Z, Liu C-H, Huang S, Fu Z, Tomita Y, Britton WR, et al. Wnt signaling activates MFSD2A to suppress vascular endothelial transcytosis and maintain blood-retinal barrier. Sci Adv. 2020;6(35):eaba7457.","journal-title":"Sci Adv"},{"key":"373_CR90","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.phrs.2015.12.024","volume":"104","author":"JZ Wang","year":"2016","unstructured":"Wang JZ, Xiao N, Zhang YZ, Zhao CX, Guo XH, Lu LM. Mfsd2a-based pharmacological strategies for drug delivery across the blood-brain barrier. Pharmacol Res. 2016;104:124\u201331.","journal-title":"Pharmacol Res"},{"issue":"9","key":"373_CR91","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202001997","volume":"10","author":"X Ju","year":"2021","unstructured":"Ju X, Miao T, Chen H, Ni J, Han L. Overcoming Mfsd2a-mediated low transcytosis to boost nanoparticle delivery to brain for chemotherapy of brain metastases. Adv Healthc Mater. 2021;10(9): e2001997.","journal-title":"Adv Healthc Mater"},{"issue":"3","key":"373_CR92","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1083\/jcb.121.3.553","volume":"121","author":"A Lutcke","year":"1993","unstructured":"Lutcke A, Jansson S, Parton RG, Chavrier P, Valencia A, Huber LA, et al. Rab17, a novel small GTPase, is specific for epithelial cells and is induced during cell polarization. J Cell Biol. 1993;121(3):553\u201364.","journal-title":"J Cell Biol"},{"issue":"4","key":"373_CR93","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1083\/jcb.200809122","volume":"185","author":"S Tzaban","year":"2009","unstructured":"Tzaban S, Massol RH, Yen E, Hamman W, Frank SR, Lapierre LA, et al. The recycling and transcytotic pathways for IgG transport by FcRn are distinct and display an inherent polarity. J Cell Biol. 2009;185(4):673\u201384.","journal-title":"J Cell Biol"},{"issue":"36","key":"373_CR94","doi-asserted-by":"publisher","first-page":"11929","DOI":"10.1523\/JNEUROSCI.1860-14.2014","volume":"34","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O\u2019Keeffe S, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. 2014;34(36):11929\u201347.","journal-title":"J Neurosci"},{"issue":"11","key":"373_CR95","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1016\/j.celrep.2017.11.055","volume":"21","author":"R Villasenor","year":"2017","unstructured":"Villasenor R, Schilling M, Sundaresan J, Lutz Y, Collin L. Sorting tubules regulate blood-brain barrier transcytosis. Cell Rep. 2017;21(11):3256\u201370.","journal-title":"Cell Rep"},{"issue":"48","key":"373_CR96","doi-asserted-by":"publisher","first-page":"eabc4397","DOI":"10.1126\/sciadv.abc4397","volume":"6","author":"X Tian","year":"2020","unstructured":"Tian X, Leite DM, Scarpa E, Nyberg S, Fullstone G, Forth J, et al. On the shuttling across the blood-brain barrier via tubule formation: Mechanism and cargo avidity bias. Sci Adv. 2020;6(48):eabc4397.","journal-title":"Sci Adv"},{"issue":"1","key":"373_CR97","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12987-022-00334-y","volume":"19","author":"P Alam","year":"2022","unstructured":"Alam P, Holst MR, Lauritsen L, Nielsen J, Nielsen SSE, Jensen PH, et al. Polarized alpha-synuclein trafficking and transcytosis across brain endothelial cells via Rab7-decorated carriers. Fluids Barriers CNS. 2022;19(1):37.","journal-title":"Fluids Barriers CNS"},{"issue":"7693","key":"373_CR98","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nature25739","volume":"554","author":"M Vanlandewijck","year":"2018","unstructured":"Vanlandewijck M, He L, Mae MA, Andrae J, Ando K, Del Gaudio F, et al. A molecular atlas of cell types and zonation in the brain vasculature. Nature. 2018;554(7693):475\u201380.","journal-title":"Nature"},{"issue":"10","key":"373_CR99","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/s41593-018-0234-x","volume":"21","author":"MD Sweeney","year":"2018","unstructured":"Sweeney MD, Kisler K, Montagne A, Toga AW, Zlokovic BV. The role of brain vasculature in neurodegenerative disorders. Nat Neurosci. 2018;21(10):1318\u201331.","journal-title":"Nat Neurosci"},{"issue":"1","key":"373_CR100","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.1038\/s41467-021-24323-1","volume":"12","author":"K Kucharz","year":"2021","unstructured":"Kucharz K, Kristensen K, Johnsen KB, Lund MA, L\u00f8nstrup M, Moos T, et al. Post-capillary venules are the key locus for transcytosis-mediated brain delivery of therapeutic nanoparticles. Nat Commun. 2021;12(1):4121.","journal-title":"Nat Commun"},{"issue":"1","key":"373_CR101","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1152\/physrev.00050.2017","volume":"99","author":"MD Sweeney","year":"2019","unstructured":"Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV. Blood-brain barrier: from physiology to disease and back. Physiol Rev. 2019;99(1):21\u201378.","journal-title":"Physiol Rev"},{"issue":"1","key":"373_CR102","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12987-020-00209-0","volume":"17","author":"W Zhang","year":"2020","unstructured":"Zhang W, Liu QY, Haqqani AS, Leclerc S, Liu Z, Fauteux F, et al. Differential expression of receptors mediating receptor-mediated transcytosis (RMT) in brain microvessels, brain parenchyma and peripheral tissues of the mouse and the human. Fluids Barriers CNS. 2020;17(1):47.","journal-title":"Fluids Barriers CNS"},{"issue":"5","key":"373_CR103","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/j.ymthe.2021.01.027","volume":"29","author":"H Morimoto","year":"2021","unstructured":"Morimoto H, Kida S, Yoden E, Kinoshita M, Tanaka N, Yamamoto R, et al. Clearance of heparan sulfate in the brain prevents neurodegeneration and neurocognitive impairment in MPS II mice. Mol Ther. 2021;29(5):1853\u201361.","journal-title":"Mol Ther"},{"issue":"1","key":"373_CR104","doi-asserted-by":"publisher","first-page":"18632","DOI":"10.1038\/s41598-019-55136-4","volume":"9","author":"RJ Boado","year":"2019","unstructured":"Boado RJ, Lu JZ, Hui EK, Lin H, Pardridge WM. Bi-functional IgG-lysosomal enzyme fusion proteins for brain drug delivery. Sci Rep. 2019;9(1):18632.","journal-title":"Sci Rep"},{"issue":"5","key":"373_CR105","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0156452","volume":"11","author":"M Salvalaio","year":"2016","unstructured":"Salvalaio M, Rigon L, Belletti D, D\u2019Avanzo F, Pederzoli F, Ruozi B, et al. Targeted polymeric nanoparticles for brain delivery of high molecular weight molecules in lysosomal storage disorders. PLoS ONE. 2016;11(5): e0156452.","journal-title":"PLoS ONE"},{"key":"373_CR106","doi-asserted-by":"crossref","unstructured":"Rigon L, Salvalaio M, Pederzoli F, Legnini E, Duskey JT, D'Avanzo F, et al. Targeting Brain Disease in MPSII: Preclinical Evaluation of IDS-Loaded PLGA Nanoparticles. Int J Mol Sci. 2019;20(8).","DOI":"10.3390\/ijms20082014"},{"issue":"2","key":"373_CR107","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ymgme.2017.11.013","volume":"123","author":"L Ou","year":"2018","unstructured":"Ou L, Przybilla MJ, Koniar B, Whitley CB. RTB lectin-mediated delivery of lysosomal \u03b1-l-iduronidase mitigates disease manifestations systemically including the central nervous system. Mol Genet Metab. 2018;123(2):105\u201311.","journal-title":"Mol Genet Metab"},{"key":"373_CR108","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13023-015-0356-0","volume":"10","author":"SY Cho","year":"2015","unstructured":"Cho SY, Lee J, Ko AR, Kwak MJ, Kim S, Sohn YB, et al. Effect of systemic high dose enzyme replacement therapy on the improvement of CNS defects in a mouse model of mucopolysaccharidosis type II. Orphanet J Rare Dis. 2015;10:141.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"373_CR109","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1021\/acs.molpharmaceut.6b00037","volume":"13","author":"RJ Boado","year":"2016","unstructured":"Boado RJ, Lu JZ, Hui EK, Lin H, Pardridge WM. Insulin receptor antibody-alpha-N-Acetylglucosaminidase fusion protein penetrates the primate blood-brain barrier and reduces glycosoaminoglycans in sanfilippo type B fibroblasts. Mol Pharm. 2016;13(4):1385\u201392.","journal-title":"Mol Pharm"},{"issue":"9","key":"373_CR110","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1021\/acs.molpharmaceut.6b00456","volume":"13","author":"RJ Boado","year":"2016","unstructured":"Boado RJ, Hui EK, Lu JZ, Pardridge WM. Very high plasma concentrations of a monoclonal antibody against the human insulin receptor are produced by subcutaneous injection in the rhesus monkey. Mol Pharm. 2016;13(9):3241\u20136.","journal-title":"Mol Pharm"},{"issue":"1","key":"373_CR111","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13023-018-0849-8","volume":"13","author":"R Giugliani","year":"2018","unstructured":"Giugliani R, Giugliani L, de Oliveira PF, Donis KC, Corte AD, Schmidt M, et al. Neurocognitive and somatic stabilization in pediatric patients with severe Mucopolysaccharidosis Type I after 52 weeks of intravenous brain-penetrating insulin receptor antibody-iduronidase fusion protein (valanafusp alpha): an open label phase 1\u20132 trial. Orphanet J Rare Dis. 2018;13(1):110.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"373_CR112","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/gim.2015.36","volume":"18","author":"J Muenzer","year":"2016","unstructured":"Muenzer J, Hendriksz CJ, Fan Z, Vijayaraghavan S, Perry V, Santra S, et al. A phase I\/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II. Genet Med. 2016;18(1):73\u201381.","journal-title":"Genet Med"},{"key":"373_CR113","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1750-1172-8-42","volume":"8","author":"YB Sohn","year":"2013","unstructured":"Sohn YB, Cho SY, Park SW, Kim SJ, Ko AR, Kwon EK, et al. Phase I\/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter syndrome). Orphanet J Rare Dis. 2013;8:42.","journal-title":"Orphanet J Rare Dis"},{"key":"373_CR114","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ymgme.2017.10.007","volume":"122S","author":"M Scarpa","year":"2017","unstructured":"Scarpa M, Orchard PJ, Schulz A, Dickson PI, Haskins ME, Escolar ML, et al. Treatment of brain disease in the mucopolysaccharidoses. Mol Genet Metab. 2017;122S:25\u201334.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"373_CR115","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ymthe.2018.12.005","volume":"27","author":"T Okuyama","year":"2019","unstructured":"Okuyama T, Eto Y, Sakai N, Minami K, Yamamoto T, Sonoda H, et al. Iduronate-2-sulfatase with anti-human transferrin receptor antibody for neuropathic mucopolysaccharidosis II: a phase 1\/2 trial. Mol Ther. 2019;27(2):456\u201364.","journal-title":"Mol Ther"},{"issue":"7","key":"373_CR116","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1016\/j.ymthe.2021.03.019","volume":"29","author":"R Giugliani","year":"2021","unstructured":"Giugliani R, Martins AM, So S, Yamamoto T, Yamaoka M, Ikeda T, et al. Iduronate-2-sulfatase fused with anti-hTfR antibody, pabinafusp alfa, for MPS-II: A phase 2 trial in Brazil. Mol Ther. 2021;29(7):2378\u201386.","journal-title":"Mol Ther"},{"issue":"3","key":"373_CR117","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ymgme.2016.05.006","volume":"118","author":"SA Jones","year":"2016","unstructured":"Jones SA, Breen C, Heap F, Rust S, de Ruijter J, Tump E, et al. A phase 1\/2 study of intrathecal heparan-N-sulfatase in patients with mucopolysaccharidosis IIIA. Mol Genet Metab. 2016;118(3):198\u2013205.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"373_CR118","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ymgme.2018.10.006","volume":"126","author":"FA Wijburg","year":"2019","unstructured":"Wijburg FA, Whitley CB, Muenzer J, Gasperini S, Del Toro M, Muschol N, et al. Intrathecal heparan-N-sulfatase in patients with Sanfilippo syndrome type A: a phase IIb randomized trial. Mol Genet Metab. 2019;126(2):121\u201330.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"373_CR119","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ymgme.2018.12.003","volume":"126","author":"CB Whitley","year":"2019","unstructured":"Whitley CB, Vijay S, Yao B, Pineda M, Parker GJM, Rojas-Caro S, et al. Final results of the phase 1\/2, open-label clinical study of intravenous recombinant human N-acetyl-\u03b1-d-glucosaminidase (SBC-103) in children with mucopolysaccharidosis IIIB. Mol Genet Metab. 2019;126(2):131\u20138.","journal-title":"Mol Genet Metab"},{"issue":"10","key":"373_CR120","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1002\/ajmg.a.37172","volume":"167","author":"BK Burton","year":"2015","unstructured":"Burton BK, Berger KI, Lewis GD, Tarnopolsky M, Treadwell M, Mitchell JJ, et al. Safety and physiological effects of two different doses of elosulfase alfa in patients with morquio a syndrome: A randomized, double-blind, pilot study. Am J Med Genet A. 2015;167(10):2272\u201381.","journal-title":"Am J Med Genet A"},{"issue":"2","key":"373_CR121","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ymgme.2014.08.012","volume":"114","author":"CJ Hendriksz","year":"2015","unstructured":"Hendriksz CJ, Giugliani R, Harmatz P, Mengel E, Guffon N, Valayannopoulos V, et al. Multi-domain impact of elosufase alfa in Morquio A syndrome in the pivotal phase III trial. Mol Genet Metab. 2015;114(2):178\u201385.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"373_CR122","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ymgme.2020.01.003","volume":"129","author":"RY Wang","year":"2020","unstructured":"Wang RY, da Silva Franco JF, L\u00f3pez-Valdez J, Martins E, Sutton VR, Whitley CB, et al. The long-term safety and efficacy of vestronidase alfa, rhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis VII. Mol Genet Metab. 2020;129(3):219\u201327.","journal-title":"Mol Genet Metab"},{"issue":"5","key":"373_CR123","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s40262-018-0721-y","volume":"58","author":"Y Qi","year":"2019","unstructured":"Qi Y, McKeever K, Taylor J, Haller C, Song W, Jones SA, et al. Pharmacokinetic and pharmacodynamic modeling to optimize the dose of vestronidase alfa, an enzyme replacement therapy for treatment of patients with mucopolysaccharidosis type VII: results from three trials. Clin Pharmacokinet. 2019;58(5):673\u201383.","journal-title":"Clin Pharmacokinet"},{"key":"373_CR124","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/978-1-4939-8958-4_9","volume":"1904","author":"T Kuramochi","year":"2019","unstructured":"Kuramochi T, Igawa T, Tsunoda H, Hattori K. Humanization and simultaneous optimization of monoclonal antibody. Methods Mol Biol. 2019;1904:213\u201330.","journal-title":"Methods Mol Biol"},{"issue":"2","key":"373_CR125","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ymgme.2015.11.001","volume":"117","author":"PS Kishnani","year":"2016","unstructured":"Kishnani PS, Dickson PI, Muldowney L, Lee JJ, Rosenberg A, Abichandani R, et al. Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction. Mol Genet Metab. 2016;117(2):66\u201383.","journal-title":"Mol Genet Metab"},{"issue":"7","key":"373_CR126","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2015.14","volume":"4","author":"L Doessegger","year":"2015","unstructured":"Doessegger L, Banholzer ML. Clinical development methodology for infusion-related reactions with monoclonal antibodies. Clin Transl Immunol. 2015;4(7): e39.","journal-title":"Clin Transl Immunol"},{"issue":"11","key":"373_CR127","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/gim.2018.29","volume":"20","author":"JB Eisengart","year":"2018","unstructured":"Eisengart JB, Rudser KD, Xue Y, Orchard P, Miller W, Lund T, et al. Long-term outcomes of systemic therapies for Hurler syndrome: an international multicenter comparison. Genet Med. 2018;20(11):1423\u20139.","journal-title":"Genet Med"},{"issue":"1\u20132","key":"373_CR128","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ymgme.2015.06.002","volume":"116","author":"EG Shapiro","year":"2015","unstructured":"Shapiro EG, Nestrasil I, Rudser K, Delaney K, Kovac V, Ahmed A, et al. Neurocognition across the spectrum of mucopolysaccharidosis type I: age, severity, and treatment. Mol Genet Metab. 2015;116(1\u20132):61\u20138.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"373_CR129","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1542\/peds.2006-2156","volume":"120","author":"JE Wraith","year":"2007","unstructured":"Wraith JE, Beck M, Lane R, van der Ploeg A, Shapiro E, Xue Y, et al. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase). Pediatrics. 2007;120(1):e37-46.","journal-title":"Pediatrics"},{"issue":"13","key":"373_CR130","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1182\/blood-2014-11-608075","volume":"125","author":"M Aldenhoven","year":"2015","unstructured":"Aldenhoven M, Wynn RF, Orchard PJ, O\u2019Meara A, Veys P, Fischer A, et al. Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study. Blood. 2015;125(13):2164\u201372.","journal-title":"Blood"},{"issue":"2","key":"373_CR131","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/jhg.2016.133","volume":"62","author":"C Kim","year":"2017","unstructured":"Kim C, Seo J, Chung Y, Ji HJ, Lee J, Sohn J, et al. Comparative study of idursulfase beta and idursulfase in vitro and in vivo. J Hum Genet. 2017;62(2):167\u201374.","journal-title":"J Hum Genet"},{"key":"373_CR132","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173562","volume":"888","author":"W Kong","year":"2020","unstructured":"Kong W, Yao Y, Zhang J, Lu C, Ding Y, Meng Y. Update of treatment for mucopolysaccharidosis type III (sanfilippo syndrome). Eur J Pharmacol. 2020;888: 173562.","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"373_CR133","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.3390\/ijms21041517","volume":"21","author":"K Sawamoto","year":"2020","unstructured":"Sawamoto K, \u00c1lvarez Gonz\u00e1lez JV, Piechnik M, Otero FJ, Couce ML, Suzuki Y, et al. Mucopolysaccharidosis IVA: diagnosis, treatment, and management. Int J Mol Sci. 2020;21(4):1517.","journal-title":"Int J Mol Sci"},{"issue":"24","key":"373_CR134","doi-asserted-by":"publisher","first-page":"13456","DOI":"10.3390\/ijms222413456","volume":"22","author":"F D'Avanzo","year":"2021","unstructured":"D\u2019Avanzo F, Zanetti A, De Filippis C, Tomanin R. Mucopolysaccharidosis Type VI, an updated overview of the disease. Int J Mol Sci. 2021;22(24):13456.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"373_CR135","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ymgme.2010.09.010","volume":"102","author":"S Turbeville","year":"2011","unstructured":"Turbeville S, Nicely H, Rizzo JD, Pedersen TL, Orchard PJ, Horwitz ME, et al. Clinical outcomes following hematopoietic stem cell transplantation for the treatment of mucopolysaccharidosis VI. Mol Genet Metab. 2011;102(2):111\u20135.","journal-title":"Mol Genet Metab"},{"issue":"7","key":"373_CR136","doi-asserted-by":"publisher","first-page":"e226","DOI":"10.1016\/j.bbmt.2019.02.012","volume":"25","author":"M Taylor","year":"2019","unstructured":"Taylor M, Khan S, Stapleton M, Wang J, Chen J, Wynn R, et al. Hematopoietic stem cell transplantation for mucopolysaccharidoses: past, present, and future. Biol Blood Marrow Transpl. 2019;25(7):e226\u201346.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"3","key":"373_CR137","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ymgme.2017.05.016","volume":"121","author":"SA Khan","year":"2017","unstructured":"Khan SA, Peracha H, Ballhausen D, Wiesbauer A, Rohrbach M, Gautschi M, et al. Epidemiology of mucopolysaccharidoses. Mol Genet Metab. 2017;121(3):227\u201340.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"373_CR138","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s13353-014-0262-5","volume":"56","author":"A Jurecka","year":"2015","unstructured":"Jurecka A, \u0141ugowska A, Golda A, Czartoryska B, Tylki-Szyma\u0144ska A. Prevalence rates of mucopolysaccharidoses in Poland. J Appl Genet. 2015;56(2):205\u201310.","journal-title":"J Appl Genet"},{"issue":"1","key":"373_CR139","doi-asserted-by":"publisher","DOI":"10.1590\/1678-4685-gmb-2020-0138","volume":"44","author":"JA Josahkian","year":"2021","unstructured":"Josahkian JA, Trapp FB, Burin MG, Michelin-Tirelli K, Magalh\u00e3es A, Sebasti\u00e3o FM, et al. Updated birth prevalence and relative frequency of mucopolysaccharidoses across Brazilian regions. Genet Mol Biol. 2021;44(1): e20200138.","journal-title":"Genet Mol Biol"},{"issue":"2","key":"373_CR140","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/sj.ejhg.5201044","volume":"12","author":"R Pinto","year":"2004","unstructured":"Pinto R, Caseiro C, Lemos M, Lopes L, Fontes A, Ribeiro H, et al. Prevalence of lysosomal storage diseases in Portugal. Eur J Hum Genet. 2004;12(2):87\u201392.","journal-title":"Eur J Hum Genet"},{"issue":"4","key":"373_CR141","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s10545-010-9093-7","volume":"33","author":"H Poupetov\u00e1","year":"2010","unstructured":"Poupetov\u00e1 H, Ledvinov\u00e1 J, Bern\u00e1 L, Dvor\u00e1kov\u00e1 L, Kozich V, Elleder M. The birth prevalence of lysosomal storage disorders in the Czech Republic: comparison with data in different populations. J Inherit Metab Dis. 2010;33(4):387\u201396.","journal-title":"J Inherit Metab Dis"},{"issue":"11","key":"373_CR142","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1111\/j.1651-2227.2008.00965.x","volume":"97","author":"G Malm","year":"2008","unstructured":"Malm G, Lund AM, M\u00e5nsson JE, Heiberg A. Mucopolysaccharidoses in the Scandinavian countries: incidence and prevalence. Acta Paediatr. 2008;97(11):1577\u201381.","journal-title":"Acta Paediatr"},{"issue":"5","key":"373_CR143","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/0092-8674(92)90307-X","volume":"70","author":"P van der Sluijs","year":"1992","unstructured":"van der Sluijs P, Hull M, Webster P, M\u00e2le P, Goud B, Mellman I. The small GTP-binding protein rab4 controls an early sorting event on the endocytic pathway. Cell. 1992;70(5):729\u201340.","journal-title":"Cell"},{"issue":"18","key":"373_CR144","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1016\/S0960-9822(01)00442-0","volume":"11","author":"M Roberts","year":"2001","unstructured":"Roberts M, Barry S, Woods A, van der Sluijs P, Norman J. PDGF-regulated rab4-dependent recycling of alphavbeta3 integrin from early endosomes is necessary for cell adhesion and spreading. Curr Biol. 2001;11(18):1392\u2013402.","journal-title":"Curr Biol"},{"issue":"9","key":"373_CR145","doi-asserted-by":"publisher","first-page":"E261","DOI":"10.1371\/journal.pbio.0020261","volume":"2","author":"C Schnatwinkel","year":"2004","unstructured":"Schnatwinkel C, Christoforidis S, Lindsay MR, Uttenweiler-Joseph S, Wilm M, Parton RG, et al. The Rab5 effector Rabankyrin-5 regulates and coordinates different endocytic mechanisms. PLoS Biol. 2004;2(9):E261.","journal-title":"PLoS Biol"},{"issue":"4","key":"373_CR146","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1091\/mbc.e04-08-0735","volume":"16","author":"ES Ward","year":"2005","unstructured":"Ward ES, Martinez C, Vaccaro C, Zhou J, Tang Q, Ober RJ. From sorting endosomes to exocytosis: association of Rab4 and Rab11 GTPases with the Fc receptor, FcRn, during recycling. Mol Biol Cell. 2005;16(4):2028\u201338.","journal-title":"Mol Biol Cell"},{"issue":"5","key":"373_CR147","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/0092-8674(92)90306-W","volume":"70","author":"C Bucci","year":"1992","unstructured":"Bucci C, Parton RG, Mather IH, Stunnenberg H, Simons K, Hoflack B, et al. The small GTPase rab5 functions as a regulatory factor in the early endocytic pathway. Cell. 1992;70(5):715\u201328.","journal-title":"Cell"},{"issue":"18","key":"373_CR148","doi-asserted-by":"publisher","first-page":"12110","DOI":"10.1074\/jbc.M809277200","volume":"284","author":"PA Vanlandingham","year":"2009","unstructured":"Vanlandingham PA, Ceresa BP. Rab7 regulates late endocytic trafficking downstream of multivesicular body biogenesis and cargo sequestration. J Biol Chem. 2009;284(18):12110\u201324.","journal-title":"J Biol Chem"},{"issue":"3","key":"373_CR149","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/tra.12143","volume":"15","author":"E Girard","year":"2014","unstructured":"Girard E, Chmiest D, Fournier N, Johannes L, Paul JL, Vedie B, et al. Rab7 is functionally required for selective cargo sorting at the early endosome. Traffic. 2014;15(3):309\u201326.","journal-title":"Traffic"},{"issue":"3","key":"373_CR150","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1042\/BSR20090032","volume":"29","author":"M Zhang","year":"2009","unstructured":"Zhang M, Chen L, Wang S, Wang T. Rab7: roles in membrane trafficking and disease. Biosci Rep. 2009;29(3):193\u2013209.","journal-title":"Biosci Rep"},{"issue":"7","key":"373_CR151","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.1091\/mbc.e05-08-0799","volume":"17","author":"CM Babbey","year":"2006","unstructured":"Babbey CM, Ahktar N, Wang E, Chen CC, Grant BD, Dunn KW. Rab10 regulates membrane transport through early endosomes of polarized Madin-Darby canine kidney cells. Mol Biol Cell. 2006;17(7):3156\u201375.","journal-title":"Mol Biol Cell"},{"issue":"4","key":"373_CR152","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s10456-021-09791-9","volume":"24","author":"SJ Gross","year":"2021","unstructured":"Gross SJ, Webb AM, Peterlin AD, Durrant JR, Judson RJ, Raza Q, et al. Notch regulates vascular collagen IV basement membrane through modulation of lysyl hydroxylase 3 trafficking. Angiogenesis. 2021;24(4):789\u2013805.","journal-title":"Angiogenesis"},{"issue":"4","key":"373_CR153","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1083\/jcb.135.4.913","volume":"135","author":"O Ullrich","year":"1996","unstructured":"Ullrich O, Reinsch S, Urb\u00e9 S, Zerial M, Parton RG. Rab11 regulates recycling through the pericentriolar recycling endosome. J Cell Biol. 1996;135(4):913\u201324.","journal-title":"J Cell Biol"},{"issue":"4","key":"373_CR154","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1091\/mbc.e04-10-0867","volume":"16","author":"JG Lock","year":"2005","unstructured":"Lock JG, Stow JL. Rab11 in recycling endosomes regulates the sorting and basolateral transport of E-cadherin. Mol Biol Cell. 2005;16(4):1744\u201355.","journal-title":"Mol Biol Cell"},{"issue":"10","key":"373_CR155","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1111\/j.1600-0854.2011.01240.x","volume":"12","author":"T Matsui","year":"2011","unstructured":"Matsui T, Itoh T, Fukuda M. Small GTPase Rab12 regulates constitutive degradation of transferrin receptor. Traffic. 2011;12(10):1432\u201343.","journal-title":"Traffic"},{"issue":"4","key":"373_CR156","doi-asserted-by":"publisher","first-page":"155","DOI":"10.4161\/cl.1.4.18152","volume":"1","author":"T Matsui","year":"2011","unstructured":"Matsui T, Fukuda M. Small GTPase Rab12 regulates transferrin receptor degradation: implications for a novel membrane trafficking pathway from recycling endosomes to lysosomes. Cell Logist. 2011;1(4):155\u20138.","journal-title":"Cell Logist"},{"issue":"7","key":"373_CR157","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1128\/MCB.26.7.2595-2614.2006","volume":"26","author":"JG Magad\u00e1n","year":"2006","unstructured":"Magad\u00e1n JG, Barbieri MA, Mesa R, Stahl PD, Mayorga LS. Rab22a regulates the sorting of transferrin to recycling endosomes. Mol Cell Biol. 2006;26(7):2595\u2013614.","journal-title":"Mol Cell Biol"},{"issue":"22","key":"373_CR158","doi-asserted-by":"publisher","first-page":"4720","DOI":"10.1091\/mbc.e09-06-0453","volume":"20","author":"H Zhu","year":"2009","unstructured":"Zhu H, Liang Z, Li G. Rabex-5 is a Rab22 effector and mediates a Rab22-Rab5 signaling cascade in endocytosis. Mol Biol Cell. 2009;20(22):4720\u20139.","journal-title":"Mol Biol Cell"},{"issue":"3","key":"373_CR159","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1083\/jcb.201512024","volume":"213","author":"PS Mrozowska","year":"2016","unstructured":"Mrozowska PS, Fukuda M. Regulation of podocalyxin trafficking by Rab small GTPases in 2D and 3D epithelial cell cultures. J Cell Biol. 2016;213(3):355\u201369.","journal-title":"J Cell Biol"},{"issue":"28","key":"373_CR160","doi-asserted-by":"publisher","first-page":"11631","DOI":"10.1074\/jbc.M116.773333","volume":"292","author":"A Biesemann","year":"2017","unstructured":"Biesemann A, Gorontzi A, Barr F, Gerke V. Rab35 protein regulates evoked exocytosis of endothelial Weibel-Palade bodies. J Biol Chem. 2017;292(28):11631\u201340.","journal-title":"J Biol Chem"},{"issue":"7","key":"373_CR161","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1002\/ijc.31569","volume":"143","author":"HT Tzeng","year":"2018","unstructured":"Tzeng HT, Su CC, Chang CP, Lai WW, Su WC, Wang YC. Rab37 in lung cancer mediates exocytosis of soluble ST2 and thus skews macrophages toward tumor-suppressing phenotype. Int J Cancer. 2018;143(7):1753\u201363.","journal-title":"Int J Cancer"},{"issue":"Pt 20","key":"373_CR162","first-page":"4780","volume":"125","author":"S Zografou","year":"2012","unstructured":"Zografou S, Basagiannis D, Papafotika A, Shirakawa R, Horiuchi H, Auerbach D, et al. A complete Rab screening reveals novel insights in Weibel-Palade body exocytosis. J Cell Sci. 2012;125(Pt 20):4780\u201390.","journal-title":"J Cell Sci"},{"issue":"4","key":"373_CR163","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1021\/mp200136x","volume":"8","author":"RJ Boado","year":"2011","unstructured":"Boado RJ, Hui EK, Lu JZ, Zhou QH, Pardridge WM. Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous Trojan horse-iduronidase fusion protein. Mol Pharm. 2011;8(4):1342\u201350.","journal-title":"Mol Pharm"},{"issue":"1","key":"373_CR164","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ymgme.2012.02.006","volume":"106","author":"DA Wolf","year":"2012","unstructured":"Wolf DA, Hanson LR, Aronovich EL, Nan Z, Low WC, Frey WH 2nd, et al. Lysosomal enzyme can bypass the blood-brain barrier and reach the CNS following intranasal administration. Mol Genet Metab. 2012;106(1):131\u20134.","journal-title":"Mol Genet Metab"},{"issue":"8","key":"373_CR165","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1073\/pnas.1222742110","volume":"110","author":"D Wang","year":"2013","unstructured":"Wang D, El-Amouri SS, Dai M, Kuan CY, Hui DY, Brady RO, et al. Engineering a lysosomal enzyme with a derivative of receptor-binding domain of apoE enables delivery across the blood-brain barrier. Proc Natl Acad Sci USA. 2013;110(8):2999\u20133004.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"373_CR166","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1021\/acs.molpharmaceut.6b01166","volume":"14","author":"RJ Boado","year":"2017","unstructured":"Boado RJ, Pardridge WM. Brain and organ uptake in the rhesus monkey in vivo of recombinant iduronidase compared to an insulin receptor antibody-iduronidase fusion protein. Mol Pharm. 2017;14(4):1271\u20137.","journal-title":"Mol Pharm"},{"issue":"7","key":"373_CR167","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1089\/hum.2017.187","volume":"28","author":"LR Belur","year":"2017","unstructured":"Belur LR, Temme A, Podetz-Pedersen KM, Riedl M, Vulchanova L, Robinson N, et al. Intranasal adeno-associated virus mediated gene delivery and expression of human iduronidase in the central nervous system: a noninvasive and effective approach for prevention of neurologic disease in mucopolysaccharidosis type I. Hum Gene Ther. 2017;28(7):576\u201387.","journal-title":"Hum Gene Ther"},{"key":"373_CR168","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2021.618360","volume":"14","author":"LR Belur","year":"2021","unstructured":"Belur LR, Romero M, Lee J, Podetz-Pedersen KM, Nan Z, Riedl MS, et al. Comparative effectiveness of intracerebroventricular, intrathecal, and intranasal routes of AAV9 vector administration for genetic therapy of neurologic disease in murine mucopolysaccharidosis type I. Front Mol Neurosci. 2021;14: 618360.","journal-title":"Front Mol Neurosci"},{"issue":"24","key":"373_CR169","doi-asserted-by":"publisher","first-page":"4871","DOI":"10.1093\/hmg\/ddq420","volume":"19","author":"VA Polito","year":"2010","unstructured":"Polito VA, Abbondante S, Polishchuk RS, Nusco E, Salvia R, Cosma MP. Correction of CNS defects in the MPSII mouse model via systemic enzyme replacement therapy. Hum Mol Genet. 2010;19(24):4871\u201385.","journal-title":"Hum Mol Genet"},{"issue":"1\u20132","key":"373_CR170","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ymgme.2012.05.005","volume":"107","author":"T Higuchi","year":"2012","unstructured":"Higuchi T, Shimizu H, Fukuda T, Kawagoe S, Matsumoto J, Shimada Y, et al. Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II. Mol Genet Metab. 2012;107(1\u20132):122\u20138.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"373_CR171","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030341","volume":"7","author":"P Calias","year":"2012","unstructured":"Calias P, Papisov M, Pan J, Savioli N, Belov V, Huang Y, et al. CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorder. PLoS ONE. 2012;7(1): e30341.","journal-title":"PLoS ONE"},{"issue":"1","key":"373_CR172","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.expneurol.2011.04.004","volume":"230","author":"T Rozaklis","year":"2011","unstructured":"Rozaklis T, Beard H, Hassiotis S, Garcia AR, Tonini M, Luck A, et al. Impact of high-dose, chemically modified sulfamidase on pathology in a murine model of MPS IIIA. Exp Neurol. 2011;230(1):123\u201330.","journal-title":"Exp Neurol"},{"issue":"2","key":"373_CR173","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/mt.2011.220","volume":"20","author":"A Ruzo","year":"2012","unstructured":"Ruzo A, Garcia M, Ribera A, Villacampa P, Haurigot V, Marc\u00f3 S, et al. Liver production of sulfamidase reverses peripheral and ameliorates CNS pathology in mucopolysaccharidosis IIIA mice. Mol Ther. 2012;20(2):254\u201366.","journal-title":"Mol Ther"},{"issue":"12","key":"373_CR174","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.3390\/ijms18122594","volume":"18","author":"JK Chung","year":"2017","unstructured":"Chung JK, Pan L, Palmieri K, Youssef AS, McCauley TG. Whole body and CNS biodistribution of rhHNS in cynomolgus monkeys after intrathecal lumbar administration: treatment implications for patients with MPS IIIA. Int J Mol Sci. 2017;18(12):2594.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"373_CR175","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1021\/acs.molpharmaceut.7b00958","volume":"15","author":"RJ Boado","year":"2018","unstructured":"Boado RJ, Lu JZ, Hui EK, Pardridge WM. Reduction in brain heparan sulfate with systemic administration of an IgG trojan horse-sulfamidase fusion protein in the mucopolysaccharidosis type IIIA mouse. Mol Pharm. 2018;15(2):602\u20138.","journal-title":"Mol Pharm"},{"issue":"2","key":"373_CR176","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ymgme.2021.03.013","volume":"133","author":"SH Kan","year":"2021","unstructured":"Kan SH, Elsharkawi I, Le SQ, Prill H, Mangini L, Cooper JD, et al. Biochemical evaluation of intracerebroventricular rhNAGLU-IGF2 enzyme replacement therapy in neonatal mice with Sanfilippo B syndrome. Mol Genet Metab. 2021;133(2):185\u201392.","journal-title":"Mol Genet Metab"},{"issue":"7","key":"373_CR177","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1093\/brain\/awy126","volume":"141","author":"J Tordo","year":"2018","unstructured":"Tordo J, O\u2019Leary C, Antunes A, Palomar N, Aldrin-Kirk P, Basche M, et al. A novel adeno-associated virus capsid with enhanced neurotropism corrects a lysosomal transmembrane enzyme deficiency. Brain. 2018;141(7):2014\u201331.","journal-title":"Brain"},{"issue":"8","key":"373_CR178","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1093\/hmg\/ddx058","volume":"26","author":"C Roca","year":"2017","unstructured":"Roca C, Motas S, Marco S, Ribera A, Sanchez V, Sanchez X, et al. Disease correction by AAV-mediated gene therapy in a new mouse model of mucopolysaccharidosis type IIID. Hum Mol Genet. 2017;26(8):1535\u201351.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"373_CR179","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1021\/acs.molpharmaceut.0c00831","volume":"18","author":"F Wang","year":"2021","unstructured":"Wang F, Moen DR, Sauni C, Kan SH, Li S, Le SQ, et al. Enzyme replacement therapy for mucopolysaccharidosis IIID using recombinant human \u03b1-N-acetylglucosamine-6-sulfatase in neonatal mice. Mol Pharm. 2021;18(1):214\u201327.","journal-title":"Mol Pharm"},{"issue":"6","key":"373_CR180","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1093\/hmg\/ddm353","volume":"17","author":"S Tomatsu","year":"2008","unstructured":"Tomatsu S, Monta\u00f1o AM, Ohashi A, Gutierrez MA, Oikawa H, Oguma T, et al. Enzyme replacement therapy in a murine model of Morquio A syndrome. Hum Mol Genet. 2008;17(6):815\u201324.","journal-title":"Hum Mol Genet"},{"issue":"10","key":"373_CR181","doi-asserted-by":"publisher","first-page":"522","DOI":"10.3390\/pharmaceutics11100522","volume":"11","author":"JV \u00c1lvarez","year":"2019","unstructured":"\u00c1lvarez JV, Herrero Filgueira C, Gonz\u00e1lez AF, Col\u00f3n Mejeras C, Beiras Iglesias A, Tomatsu S, et al. Enzyme-loaded gel core nanostructured lipid carriers to improve treatment of lysosomal storage diseases: formulation and in vitro cellular studies of elosulfase alfa-loaded systems. Pharmaceutics. 2019;11(10):522.","journal-title":"Pharmaceutics"},{"issue":"1","key":"373_CR182","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/pr.2011.13","volume":"71","author":"D Auclair","year":"2012","unstructured":"Auclair D, Finnie J, Walkley SU, White J, Nielsen T, Fuller M, et al. Intrathecal recombinant human 4-sulfatase reduces accumulation of glycosaminoglycans in dura of mucopolysaccharidosis VI cats. Pediatr Res. 2012;71(1):39\u201345.","journal-title":"Pediatr Res"},{"issue":"42","key":"373_CR183","doi-asserted-by":"publisher","first-page":"17022","DOI":"10.1073\/pnas.1214779109","volume":"109","author":"HT Huynh","year":"2012","unstructured":"Huynh HT, Grubb JH, Vogler C, Sly WS. Biochemical evidence for superior correction of neuronal storage by chemically modified enzyme in murine mucopolysaccharidosis VII. Proc Natl Acad Sci USA. 2012;109(42):17022\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"21","key":"373_CR184","doi-asserted-by":"publisher","first-page":"3610","DOI":"10.1093\/hmg\/ddz220","volume":"28","author":"G Pag\u00e8s","year":"2019","unstructured":"Pag\u00e8s G, Gim\u00e9nez-Llort L, Garc\u00eda-Lareu B, Ariza L, Navarro M, Casas C, et al. Intrathecal AAVrh10 corrects biochemical and histological hallmarks of mucopolysaccharidosis VII mice and improves behavior and survival. Hum Mol Genet. 2019;28(21):3610\u201324.","journal-title":"Hum Mol Genet"},{"issue":"13","key":"373_CR185","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1093\/hmg\/ddn088","volume":"17","author":"DC Martin","year":"2008","unstructured":"Martin DC, Atmuri V, Hemming RJ, Farley J, Mort JS, Byers S, et al. A mouse model of human mucopolysaccharidosis IX exhibits osteoarthritis. Hum Mol Genet. 2008;17(13):1904\u201315.","journal-title":"Hum Mol Genet"},{"issue":"6","key":"373_CR186","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s10545-016-9974-5","volume":"39","author":"JB Hennermann","year":"2016","unstructured":"Hennermann JB, G\u00f6kce S, Solyom A, Mengel E, Schuchman EH, Simonaro CM. Treatment with pentosan polysulphate in patients with MPS I: results from an open label, randomized, monocentric phase II study. J Inherit Metab Dis. 2016;39(6):831\u20137.","journal-title":"J Inherit Metab Dis"},{"issue":"9","key":"373_CR187","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/S1474-4422(17)30169-2","volume":"16","author":"M Tardieu","year":"2017","unstructured":"Tardieu M, Z\u00e9rah M, Gougeon ML, Ausseil J, de Bournonville S, Husson B, et al. Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1\/2 clinical trial. Lancet Neurol. 2017;16(9):712\u201320.","journal-title":"Lancet Neurol"},{"key":"373_CR188","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2021.100774","volume":"28","author":"S Jones","year":"2021","unstructured":"Jones S, Coker M, L\u00f3pez AG, Sniadecki J, Mayhew J, Hensman P, et al. Open-label phase 1\/2 study of vestronidase alfa for mucopolysaccharidosis VII. Mol Genet Metab Rep. 2021;28: 100774.","journal-title":"Mol Genet Metab Rep"}],"container-title":["Fluids and Barriers of the CNS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12987-022-00373-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12987-022-00373-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12987-022-00373-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T04:03:41Z","timestamp":1663560221000},"score":1,"resource":{"primary":{"URL":"https:\/\/fluidsbarrierscns.biomedcentral.com\/articles\/10.1186\/s12987-022-00373-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,19]]},"references-count":188,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["373"],"URL":"https:\/\/doi.org\/10.1186\/s12987-022-00373-5","relation":{},"ISSN":["2045-8118"],"issn-type":[{"value":"2045-8118","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,19]]},"assertion":[{"value":"1 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors have nothing to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"76"}}